Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995 Sep;21(3):544-50
Date
09/01/1995Pubmed ID
8527541DOI
10.1093/clinids/21.3.544Scopus ID
2-s2.0-0029156103 (requires institutional sign-in at Scopus site) 75 CitationsAbstract
The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patients and on the basis of a successful outcome (absence of any infection) for clinically evaluable patients failed to detect any difference in efficacy between the two treatments. Infection was cleared in 92% of meropenem- and 89% of T/C-treated clinically evaluable patients. Eradication of pathogens also was similar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.
Author List
Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, Wilson SEMESH terms used to index this publication - Major topics in bold
AbdomenAdolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Bacterial Infections
Clindamycin
Diarrhea
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Prospective Studies
Thienamycins
Tobramycin
